Endurance Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $13.8M | Buy |
102,116
+839
| +0.8% | +$123K | 1.88% | 14 |
|
|
2023
Q1 | $16M | Buy |
101,277
+1,917
| +2% | +$293K | 2.27% | 12 |
|
|
2022
Q4 | $16.1M | Buy |
99,360
+528
| +0.5% | +$81K | 2.42% | 9 |
|
|
2022
Q3 | $13.3M | Buy |
98,832
+129
| +0.1% | +$18.5K | 2.19% | 11 |
|
|
2022
Q2 | $15.1M | Sell |
98,703
-1,015
| -1% | -$155K | 2.3% | 9 |
|
|
2022
Q1 | $16.2M | Sell |
99,718
-5,966
| -6% | -$867K | 2.09% | 10 |
|
|
2021
Q4 | $14.3M | Sell |
105,684
-7,228
| -6% | -$854K | 1.54% | 17 |
|
|
2021
Q3 | $12.2M | Sell |
112,912
-784
| -0.7% | -$89.6K | 1.35% | 20 |
|
|
2021
Q2 | $12.8M | Buy |
113,696
+679
| +0.6% | +$76.5K | 1.42% | 17 |
|
|
2021
Q1 | $12.2M | Buy |
113,017
+3,392
| +3% | +$363K | 1.44% | 17 |
|
|
2020
Q4 | $11.7M | Buy |
109,625
+620
| +0.6% | +$59.6K | 1.48% | 16 |
|
|
2020
Q3 | $9.55M | Buy |
109,005
+7,000
| +7% | +$659K | 1.41% | 19 |
|
|
2020
Q2 | $10M | Buy |
102,005
+4,647
| +5% | +$409K | 1.64% | 16 |
|
|
2020
Q1 | $7.42M | Buy |
97,358
+3,115
| +3% | +$265K | 1.43% | 20 |
|
|
2019
Q4 | $8.34M | Buy |
94,243
+9,354
| +11% | +$777K | 1.28% | 23 |
|
|
2019
Q3 | $6.43M | Sell |
84,889
-1,991
| -2% | -$137K | 1.07% | 28 |
|
|
2019
Q2 | $6.32M | Buy |
86,880
+915
| +1% | +$71.9K | 0.99% | 30 |
|
|
2019
Q1 | $6.93M | Sell |
85,965
-1,859
| -2% | -$152K | 1.13% | 27 |
|
|
2018
Q4 | $8.1M | Buy |
87,824
+1,521
| +2% | +$134K | 1.51% | 19 |
|
|
2018
Q3 | $8.16M | Sell |
86,303
-950
| -1% | -$90.1K | 1.28% | 24 |
|
|
2018
Q2 | $8.08M | Sell |
87,253
-600
| -0.7% | -$58.6K | 1.33% | 23 |
|
|
2018
Q1 | $8.31M | Sell |
87,853
-1,999
| -2% | -$220K | 1.4% | 22 |
|
|
2017
Q4 | $8.69M | Sell |
89,852
-13,450
| -13% | -$1.27M | 1.4% | 22 |
|
|
2017
Q3 | $9.18M | Sell |
103,302
-9,976
| -9% | -$759K | 1.52% | 20 |
|
|
2017
Q2 | $8.21M | Sell |
113,278
-200
| -0.2% | -$13.4K | 1.39% | 23 |
|
|
2017
Q1 | $7.39M | Buy |
113,478
+551
| +0.5% | +$34.6K | 1.28% | 26 |
|
|
2016
Q4 | $7.07M | Buy |
112,927
+6,900
| +7% | +$421K | 1.26% | 26 |
|
|
2016
Q3 | $6.71M | Sell |
106,027
-3,499
| -3% | -$227K | 1.2% | 30 |
|
|
2016
Q2 | $6.78M | Sell |
109,526
-3,550
| -3% | -$216K | 1.27% | 29 |
|
|
2016
Q1 | $6.46K | Buy |
113,076
+784
| +0.7% | +$43.7K | 0.91% | 29 |
|
|
2015
Q4 | $6.65M | Buy |
112,292
+34,453
| +44% | +$1.98M | 1.27% | 28 |
|
|
2015
Q3 | $4.34M | Buy |
77,839
+8,539
| +12% | +$556K | 0.76% | 36 |
|
|
2015
Q2 | $4.66M | Buy |
69,300
+2,650
| +4% | +$173K | 0.78% | 38 |
|
|
2015
Q1 | $3.9M | Buy |
66,650
+18,726
| +39% | +$1.13M | 0.68% | 48 |
|
|
2014
Q4 | $3.14M | Buy |
47,924
+14,132
| +42% | +$891K | 0.56% | 55 |
|
|
2014
Q3 | $1.95M | Buy |
33,792
+12,722
| +60% | +$706K | 0.36% | 69 |
|
|
2014
Q2 | $1.19M | Buy |
+21,070
| New | +$1.11M | 0.2% | 102 |
|
Other funds holding ABBV
Endurance Wealth Management's ABBV Position: Q2 2023 in Review
Endurance Wealth Management increased its AbbVie (ABBV) stake by 0.83% in Q2 2023, buying an estimated $123K and bringing the position to 102,116 shares worth $13.8M. The position accounts for 1.88% of the portfolio, ranked #14.
Endurance Wealth Management first reported a position in ABBV in Q2 2014 and has held it in 37 quarters since. The position peaked at $16.2M in Q1 2022. 3,077 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.
- Endurance Wealth Management held 102,116 shares of AbbVie worth $13.8M as of Q2 2023.
- Endurance Wealth Management bought 839 AbbVie shares in Q2 2023, an estimated $123K.
- AbbVie made up 1.88% of Endurance Wealth Management's portfolio in Q2 2023, its #14 holding.
- Endurance Wealth Management first reported a position in AbbVie in Q2 2014 and has held it in 37 quarters since.
- Endurance Wealth Management's AbbVie position peaked at $16.2M in Q1 2022.
- 3,077 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.
Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.